StemCell Therapy

Patients with splanchnic vein thrombosis (SVT) as a presenting condition of polycythemia vera (PV) or essential thrombocythemia (ET) had a higher risk of death compared with those without SVT at the time of PV or ET diagnosis, according to results of a retrospective study published in Annals of Hematology.

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including PV, ET, and primary myelofibrosis (PMF), are a group of hematopoietic stem cell disorders that result in an overproduction of red blood cells, white cells, and/or platelets. All 3 of these conditions are characterized by an increased risk of thrombosis, a major cause of morbidity in patients with these diseases.

Rarely,patients with MPN present with thrombosis in splanchnic veins, which supplyblood to the gastrointestinal tract, liver, spleen, and pancreas.

Resultsof previous studies have shown that patients with MPN presenting with SVT aremore likely to be younger and to have disease characterized by specificfeatures, such as a slower rate of disease progression. These findings suggest thatPV and ET in patients presenting with SVT may be a biologically distinct entityassociated with a specific natural history.

In this study, 113 patients with SVT at theinitial presentation of PV or ET were identified in 2 Spanish registries thatincluded 1831 and 1304 patients with PV and ET, respectively, as well as aseparate registry of 926 patients with MPN. The remaining patients with PV orET (n=3587), including those patients who developed SVT following diagnosis ofMPN, comprised the control group. The primary study outcome was survival, withsecondary outcomes including thrombosis,bleeding, disease progression, and second cancer.

Genotypinginformation, available for nearly 90% of cases and controls showed that JAK2 and CALR mutations were detectable in 97% and 2% of cases, and 87% and9% of controls, respectively. In addition MPLmutations were detected in 1.5% of controls.

Themedian ages of patients of the cases and controls were 42 years and 65 years,respectively (P =.0001). Thosepresenting with SVT were significantly more likely to be diagnosed with PVcompared with ET or an unclassified MPN (P<.0001), and to have lower hemoglobin levels (P =.0004), and higher leukocyte (P =.0004), and lower platelet counts (P =.0004) at diagnosis.

This article originally appeared on Oncology Nurse Advisor

Read this article:
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality - Hematology Advisor

This entry was posted on March 18, 2020 at 11:44 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |